BP002844-MEV-005: Recombinant Measles Virus Hemagglutinin Mosaic
Source: E. coli-derived.
Purity > 95% as determined by 10% PAGE (coomassie staining) and RP-HPLC.
Applications: ELISA, WB.BP002844-MEV-002: Recombinant Measles Virus Non-Structural C-Protein
Source: E. coli-derived.
Purity > 95% as determined by 10% PAGE (coomassie staining) and RP-HPLC.BP002844-MEV-004: Recombinant Measles Virus 89-165 a.a.
Source: E. coli-derived.
Purity > 95% as determined by 10% PAGE (coomassie staining) and RP-HPLC.
Applications: ELISA, WB.BP002844-MEV-001: Recombinant Measles Virus Large Polymerase 58-149 a.a.
Source: E. coli-derived.
Purity > 95% as determined by 10% PAGE (coomassie staining) and RP-HPLC.
Applications: ELISA, WB.BP002844-MEV-003: Recombinant Measles Virus Large Polymerase 2059-2183 a.a.
Source: E. coli-derived.
Purity > 95% as determined by 10% PAGE (coomassie staining) and RP-HPLC.
Applications: ELISA, WB.BP002538-ENZ-151: Recombinant Human N-Methylpurine-DNA Glycosylase (MPG) Enzyme
Source: E. coli-derived.
Purity: > 90.0% as determined by SDS-PAGE.BP003014-PRO-763: Recombinant Human Myeloid cell nuclear differentiation antigen (MNDA) protein
Source: E. coli-derived.
Purity: > 90.0% by SDS-PAGE.BP002590-ENZ-376: Recombinant Human Malic Enzyme 2 (ME2)
Source: E. coli-derived.
ME2 activity was assayed spectrophotometrically at 340 nm as described in Mandela and Sauer (1975). The standard reaction mixture contained 50 mM Tris.HCl, 3 mM MnCl2, 5 mM malate, 0.12 mM NADP+, 2.5 mM fumarate, Assay was performed in a Beckman spectrophotometer. The Km value is 1.5?.6 mM.
Purity: > 95.0% as determined by HPLC and SDS-PAGE.BP000226-CYT-600: Recombinant Mouse Noggin
Source: E. coli-derived.
The ED50 was determined by its ability to inhibit 5.0 ug/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 1-2 ug/ml of NOGGIN corresponding to a specific activity of 0.5-1 MIU/mg.
Purity > 95%, by SDS-PAGE.BP000226-CYT-475: Recombinant Human Noggin
Source: E. coli-derived.
The ED50 was determined by its ability to inhibit 5.0 ug/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 0.05-0.08 ug/ml of Noggin concentration corresponding to a Specific Activity of 12.5-20 MIU/mg.
Purity > 95%, by SDS-PAGE.